Palatin Technologies Inc
PTN
Company Profile
Business description
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Contact
103 Carnegie Center Drive
Suite 300
PrincetonNJ08852
USAT: +1 609 495-2200
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
29
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
Activist investor presses gold miner on selling to larger players.
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
When consistency becomes constraint.
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
The market sees risks and are discounting the shares excessively.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.90 | 58.60 | -0.65% |
| CAC 40 | 8,244.29 | 93.87 | 1.15% |
| DAX 40 | 24,944.95 | 149.01 | 0.60% |
| Dow JONES (US) | 51,552.55 | 865.48 | 1.71% |
| FTSE 100 | 10,360.32 | 28.02 | 0.27% |
| HKSE | 25,253.40 | 379.81 | -1.48% |
| NASDAQ | 26,908.46 | 54.49 | 0.20% |
| Nikkei 225 | 67,470.69 | 931.45 | -1.36% |
| NZX 50 Index | 13,101.61 | 13.47 | -0.10% |
| S&P 500 | 7,592.64 | 38.96 | 0.52% |
| S&P/ASX 200 | 8,686.10 | 59.50 | -0.68% |
| SSE Composite Index | 4,057.78 | 26.19 | -0.64% |